Focelite brings curative therapy for COVID-19 patients

Focelite, a startup at Bangalore Bioinnovation Centre (BBC), plans to launch ‘ Welblu’, an innovative solution to treat COVID-19, in collaboration with the US partner. It is a curative therapy for COVID-19 positive patients. A clinical study with this innovative solution has been performed in the US. This study has shown that COVID-19 positive patients who have undergone treatment using Welblu effectively recovered from cytokine storm and respiratory distress in the lesser meantime than the control group. Welblu has unique therapeutic action that simultaneously impacts several mechanisms related to COVID -19 complications such as severe hypoxia, hyperinflammatory reactions and the increased death signalling leading to an immunosuppressive state. Likewise, it is seen to be re-adjusting cellular metabolism to a mitochondrion–centred condition that is depriving the COVID-19 virus of energetic and structural supplies.